Table 1

 Relationships between vimentin and laminin expression and clinicopathological and immunohistochemical characteristics

Vimentin-positivep ValueLaminin-positivep Value
EGFR, epidermal growth factor receptor; ER, oestrogen receptor; PR, progesterone receptor.
*According to Nielsen et al criteria.28
Menopausal status
    Premenopausal17/99 (17.2%)17/98 (17.3%)
    Postmenopausal34/116 (29.3%)0.03722/115 (19.1%)0.737
Size
    p T121/114 (18.4%)18/114 (15.8%)
    p T223/70 (32.9%)0.02617/69 (24.6%)0.141
Grade
    14/52 (7.7%)1/52 (1.9%)
    29/57 (15.8%)7/56 (12.5%)
    334/84 (40.5%)<0.00124/83 (28.9%)<0.001
ER
    Positive11/161 (6.8%)12/160 (7.5%)
    Negative40/60 (66.7%)<0.00127/59 (45.8%)<0.001
PR
    Positive14/149 (9.4%)15/147 (10.2%)
    Negative38/74 (51.4%)<0.00124/73 (32.9%)<0.001
p53
    Positive16/60 (26.7%)17/59 (28.8%)
    Negative35/157 (22.3%)0.49722/156 (14.1%)0.012
HER2
    Positive6/37 (16.2%)8/35 (22.9%)
    Negative46/187 (24.6%)0.27031/187 (16.6%)0.370
CK5/6
    Positive20/35 (57.1%)12/35 (34.3%)
    Negative32/186(17.2%)<0.00127/184 (14.7%)0.005
EGFR
    Positive13/21 (61.9%)7/20 (35.0%)
    Negative38/191 (19.9%)<0.00130/191 (15.7%)0.031
Laminin
    Positive22/39 (56.4%)
    Negative30/181 (16.6%)<0.001
Basal-like*
    Positive21/27 (77.8%)11/26 (42.3%)
    Negative30/194 (15.5%)<0.00128/193 (14.5%)0.001